Zealand Pharma (ZEAL) Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ZEAL Community Fair Values
Create NarrativeSee what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 310.60 |
| 52 Week High | DKK 556.00 |
| 52 Week Low | DKK 233.50 |
| Beta | 0.55 |
| 1 Month Change | 3.57% |
| 3 Month Change | -22.29% |
| 1 Year Change | -25.53% |
| 3 Year Change | 16.85% |
| 5 Year Change | 61.18% |
| Change since IPO | 290.69% |
Recent News & Updates
Analysis Article • May 14
Zealand Pharma's (CPH:ZEAL) Solid Profits Have Weak Fundamentals
Unsurprisingly, Zealand Pharma A/S' ( CPH:ZEAL ) stock price was strong on the back of its healthy earnings report. We...Analysis Article • May 11
Analysts Have Made A Financial Statement On Zealand Pharma A/S' (CPH:ZEAL) First-Quarter Report
A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of first-quarter numbers that could potentially...Recent updates
Analysis Article • May 14
Zealand Pharma's (CPH:ZEAL) Solid Profits Have Weak Fundamentals
Unsurprisingly, Zealand Pharma A/S' ( CPH:ZEAL ) stock price was strong on the back of its healthy earnings report. We...Analysis Article • May 11
Analysts Have Made A Financial Statement On Zealand Pharma A/S' (CPH:ZEAL) First-Quarter Report
A week ago, Zealand Pharma A/S ( CPH:ZEAL ) came out with a strong set of first-quarter numbers that could potentially...
Narrative Update • Apr 22
ZEAL: Obesity Pipeline And AI Hub Will Support Future Re Rating
Analysts have sharply reduced their price targets on Zealand Pharma, with cuts from DKK 1,000 to DKK 460 and from DKK 450 to DKK 275. These changes reflect more cautious assumptions regarding the petrelintide obesity program and increased competitive pressures in the obesity market.Narrative Update • Apr 07
ZEAL: Obesity Partnership With Roche And AI Hub Will Drive Future Re Rating
Analysts have sharply reduced price targets on Zealand Pharma, with several firms shifting to more neutral ratings and resetting expectations to a range of around DKK 275 to DKK 460. This reflects more conservative views on petrelintide's role in a competitive obesity market.Narrative Update • Mar 24
ZEAL: Obesity Trial Partnering With Roche Will Drive Future Re-Rating Potential
The analyst price target for Zealand Pharma has been revised lower to DKK 825 from DKK 1,120, reflecting recent reductions in Street targets and more cautious views on petrelintide's potential in a crowded obesity market, even as analysts still model healthier margins and a lower future P/E multiple. Analyst Commentary Recent Street research reflects a reset in expectations for Zealand Pharma, with multiple firms cutting price targets and moving to more neutral ratings after the Phase II ZUPREME-1 and Phase 2b petrelintide obesity data.
Narrative Update • Mar 10
ZEAL: Petrelintide Obesity Data And Pipeline Progress Will Support Future Upside
The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide's obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold. Analyst Commentary Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level.Narrative Update • Feb 24
ZEAL: Positive Immunology Data And Metabolic Partnership Will Support Future Upside
Analysts have trimmed their price target on Zealand Pharma by DKK 5 to reflect updated assumptions for revenue growth, profit margins and a higher forward P/E. They have kept the overall discount rate broadly in line with prior views.Narrative Update • Feb 09
ZEAL: Metabolic Collaboration Will Drive Future Upside As Profitability Assumptions Improve
Analysts have trimmed their price target for Zealand Pharma from €745.93 to €735.27, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that modestly adjust their overall valuation framework. What's in the News Zealand Pharma and OTR Therapeutics entered a multi program collaboration and license agreement focused on discovering and developing novel therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).Narrative Update • Jan 25
ZEAL: Metabolic Collaboration Will Support Future Upside As Margins Strengthen
Analysts see Zealand Pharma’s fair value estimate broadly unchanged at around €745.93 per share. The updated target reflects slightly firmer profit margin assumptions at 26.94%, a modestly smaller 36.49% revenue decline, and a lower forward P/E of 94.77x, partly offset by a marginally higher 5.17% discount rate.Narrative Update • Jan 10
ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value
Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).Analysis Article • Jan 03
Zealand Pharma A/S' (CPH:ZEAL) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 3.5x Zealand Pharma A/S ( CPH:ZEAL ) may be sending very bullish signals at...Narrative Update • Dec 25
ZEAL: Next Generation Metabolic Partnership Will Drive Future Upside Potential
Analysts have nudged their price target for Zealand Pharma slightly higher to approximately $774 per share from about $773, citing modestly lower discount rate assumptions. These more than offset slightly weaker long term revenue growth and profit margin expectations.Analysis Article • Dec 11
Zealand Pharma (CPH:ZEAL) Has A Rock Solid Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative Update • Dec 11
ZEAL: Future Index Exit And Margin Resilience Will Unlock Upside
Analysts have trimmed their price target on Zealand Pharma by approximately kr20 to around kr773. This reflects slightly higher perceived risk, more conservative revenue growth expectations, and a modest reduction in long term profit margin assumptions, despite still rich forward valuation multiples.Narrative Update • Nov 27
ZEAL: Future Discount Rate Shift Will Unlock Undervalued Potential
Analysts have revised Zealand Pharma's price target downward from $818.80 to $793.06. This adjustment primarily reflects reduced growth expectations and a slightly higher discount rate in their updated models.Analysis Article • Nov 16
Zealand Pharma A/S (CPH:ZEAL) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Zealand Pharma A/S ( CPH:ZEAL ) just released its latest third-quarter results and things are looking bullish. Revenue...Narrative Update • Sep 05
Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks
Analysts maintain a positive long-term outlook on Zealand Pharma despite near-term competitive and pipeline risks, leading to a modest consensus price target reduction from DKK835.47 to DKK818.80 as updated risk assessments are incorporated. Analyst Commentary Bullish analysts cite attractive entry points at current share levels, suggesting the stock is undervalued given long-term growth potential.Analysis Article • Aug 29
Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Zealand Pharma A/S ( CPH:ZEAL ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...New Narrative • Aug 17
Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks
Key Takeaways Major data from obesity drug trials and new industry alliances position the company for expanded future revenues, lowered commercialization risks, and greater global market access. Strong financial reserves enable self-funded innovation and product launches, with pipeline diversification aligning well with emerging trends in obesity treatment.Analysis Article • Aug 17
Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results
CPSE:ZEAL 1 Year Share Price vs Fair Value Explore Zealand Pharma's Fair Values from the Community and select yours...Analysis Article • May 24
Is Zealand Pharma (CPH:ZEAL) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 21
Most Shareholders Will Probably Find That The CEO Compensation For Zealand Pharma A/S (CPH:ZEAL) Is Reasonable
Key Insights Zealand Pharma to hold its Annual General Meeting on 27th of March CEO Adam Steensberg's total...Analysis Article • Feb 21
Zealand Pharma A/S (CPH:ZEAL) Analysts Are Way More Bearish Than They Used To Be
One thing we could say about the analysts on Zealand Pharma A/S ( CPH:ZEAL ) - they aren't optimistic, having just made...Analysis Article • Dec 22
Analysts Just Made A Substantial Upgrade To Their Zealand Pharma A/S (CPH:ZEAL) Forecasts
Shareholders in Zealand Pharma A/S ( CPH:ZEAL ) may be thrilled to learn that the analysts have just delivered a major...Analysis Article • Nov 09
Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher
Shareholders in Zealand Pharma A/S ( CPH:ZEAL ) may be thrilled to learn that the analysts have just delivered a major...Analysis Article • Oct 01
Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 21
Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade
Today is shaping up negative for Zealand Pharma A/S ( CPH:ZEAL ) shareholders, with the analysts delivering a...Analysis Article • Aug 18
Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Investors in Zealand Pharma A/S ( CPH:ZEAL ) had a good week, as its shares rose 6.9% to close at kr.951 following the...Shareholder Returns
| ZEAL | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | -9.0% | 0.3% | 1.6% |
| 1Y | -25.5% | 13.1% | -12.8% |
Return vs Industry: ZEAL underperformed the Danish Biotechs industry which returned 15.6% over the past year.
Return vs Market: ZEAL underperformed the Danish Market which returned -12.7% over the past year.
Price Volatility
| ZEAL volatility | |
|---|---|
| ZEAL Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 9.2% |
| 10% least volatile stocks in DK Market | 2.9% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: ZEAL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 544 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
| ZEAL fundamental statistics | |
|---|---|
| Market cap | DKK 21.94b |
| Earnings (TTM) | DKK 6.40b |
| Revenue (TTM) | DKK 9.24b |
3.4x
P/E Ratio2.4x
P/S RatioIs ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEAL income statement (TTM) | |
|---|---|
| Revenue | DKK 9.24b |
| Cost of Revenue | DKK 816.00k |
| Gross Profit | DKK 9.24b |
| Other Expenses | DKK 2.84b |
| Earnings | DKK 6.40b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 13, 2026
| Earnings per share (EPS) | 90.53 |
| Gross Margin | 99.99% |
| Net Profit Margin | 69.21% |
| Debt/Equity Ratio | 2.1% |
How did ZEAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/15 01:22 |
| End of Day Share Price | 2026/05/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zealand Pharma A/S is covered by 36 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yihan Li | Barclays |
| Kerry Holford | Berenberg |
| Laura Hindley | Berenberg |